Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
Top
Results
All apremilast studies
Meta analysis
 
Feedback
Home
←
next
study
→
previous
study
c19early.org COVID-19 treatment researchApremilastApremilast (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
All Studies   All Outcomes    Recent:   

Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

Amgen, NCT04590586, COMMUNITY, NCT04590586
Apr 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -1% Improvement Relative Risk Improvement -8% Discharge -11% Recovery -11% Apremilast  COMMUNITY  LATE TREATMENT  DB RCT Is late treatment with apremilast beneficial for COVID-19? Double-blind RCT 515 patients in the USA No significant difference in outcomes seen c19early.org Amgen, NCT04590586, April 2022 Favorsapremilast Favorscontrol 0 0.5 1 1.5 2+
RCT 384 hospitalized patients showing no significant difference with apremilast treatment.
Important missing comments or errors? Let us know.
Study covers apremilast and lanadelumab.
risk of death, 0.9% higher, RR 1.01, p = 1.00, treatment 34 of 194 (17.5%), control 33 of 190 (17.4%).
risk of no improvement, 8.1% higher, RR 1.08, p = 0.73, treatment 53 of 194 (27.3%), control 48 of 190 (25.3%).
risk of no hospital discharge, 11.3% higher, RR 1.11, p = 0.56, treatment 50 of 194 (25.8%), control 44 of 190 (23.2%).
risk of no recovery, 10.6% higher, RR 1.11, p = 0.58, treatment 61 of 194 (31.4%), control 54 of 190 (28.4%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Amgen et al., 7 Apr 2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04590586 (history) (COMMUNITY). Contact: medinfo@amgen.com.
This PaperApremilastAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0